• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Spontaneous relapse of hepatitis in inactive HBsAg carriers.HBsAg 携带者静止期肝炎的自发复发。
Hepatol Int. 2007 Jun;1(2):311-5. doi: 10.1007/s12072-007-9002-9.
2
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up.高流行地区无症状携带者的HBsAg血清学清除:长期随访期间的显著高发生率
Hepatology. 2007 May;45(5):1187-92. doi: 10.1002/hep.21612.
3
Spontaneous relapse in patients with inactive chronic hepatitis B virus infection.慢性乙型肝炎病毒感染非活动期患者的自发复发
Caspian J Intern Med. 2018 Fall;9(4):393-396. doi: 10.22088/cjim.9.4.393.
4
Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).慢性乙型肝炎病毒感染的自然史:在希腊北部进行的一项长达12年随访的队列研究(欧洲区域间合作项目I-II/EC的一部分)
J Med Virol. 2005 Oct;77(2):173-9. doi: 10.1002/jmv.20434.
5
Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.乙型肝炎表面抗原水平与恩替卡韦治疗慢性乙型肝炎病毒感染后复发的关系。
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1984-92.e1. doi: 10.1016/j.cgh.2015.06.002. Epub 2015 Jun 12.
6
A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.对谷丙转氨酶水平正常的HBeAg阳性乙肝患者进行为期三个月的拉米夫定治疗。
Turk J Gastroenterol. 2004 Mar;15(1):14-20.
7
[Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].[乙肝表面抗原(HBsAg)水平能否用于区分非活动性HBsAg携带者与HBeAg阴性慢性乙型肝炎?]
Mikrobiyol Bul. 2007 Jan;41(1):87-93.
8
Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital.在一所大学医院随访的慢性乙型肝炎患者中与自发HBsAg清除相关的因素。
Ann Hepatol. 2014 Nov-Dec;13(6):762-70.
9
Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.成人慢性乙型肝炎病毒感染的自然史,重点关注肝硬化和肝细胞癌的发生情况。
J Gastroenterol Hepatol. 2000 May;15 Suppl:E25-30. doi: 10.1046/j.1440-1746.2000.02097.x.
10
Serum HBsAg, HBeAg, anti-HBe, and hepatitis B viral DNA in asymptomatic carriers in Taiwan.台湾无症状携带者的血清乙肝表面抗原、乙肝e抗原、乙肝e抗体及乙肝病毒DNA
J Med Virol. 1986 May;19(1):87-94. doi: 10.1002/jmv.1890190113.

引用本文的文献

1
HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.赫伯纳斯瓦克:慢性乙型肝炎背景下的研发与应用
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):221-237. doi: 10.5005/jp-journals-10018-1457. Epub 2024 Dec 27.
2
A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study.聚乙二醇干扰素 α-2b 治疗产后乙型肝炎 e 抗原阴性慢性乙型肝炎病毒感染妇女的高功能性治愈率:一项探索性研究。
Front Cell Infect Microbiol. 2024 Aug 8;14:1426960. doi: 10.3389/fcimb.2024.1426960. eCollection 2024.
3
The Use of Tenofovir Disoproxil Fumarate in the Management of eAg-Negative Chronic Hepatitis B Infection.替诺福韦酯在e抗原阴性慢性乙型肝炎感染管理中的应用
J Clin Med. 2024 Mar 24;13(7):1864. doi: 10.3390/jcm13071864.
4
Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.聚乙二醇干扰素 α-2b 在慢性乙型肝炎病毒感染优势人群中诱导的临床治愈:一项回顾性队列研究。
Front Cell Infect Microbiol. 2024 Jan 16;13:1332232. doi: 10.3389/fcimb.2023.1332232. eCollection 2023.
5
Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.三重基序蛋白 19 和 38 与聚乙二醇干扰素-α治疗 HBeAg 阴性慢性乙型肝炎患者的治疗应答和 HBsAg 清除相关。
Virol J. 2023 Jul 20;20(1):161. doi: 10.1186/s12985-023-02119-7.
6
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.旨在实现慢性乙型肝炎和丁型肝炎治愈的临床试验治疗终点和研究设计指南:2022 年美国肝病研究学会-欧洲肝脏研究学会乙型肝炎-丁型肝炎治疗终点会议报告。
J Hepatol. 2023 Nov;79(5):1254-1269. doi: 10.1016/j.jhep.2023.06.002. Epub 2023 Jun 21.
7
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.慢性乙型和丁型肝炎临床治愈临床试验终点和研究设计指导:2022 年 AASLD-EASLHBV-HDV 治疗终点会议报告。
Hepatology. 2023 Nov 1;78(5):1654-1673. doi: 10.1097/HEP.0000000000000431. Epub 2023 Jun 21.
8
Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative.慢性 HBV 感染患者 HBsAg 阳性、HBV DNA 阴性、HBeAg 阴性的病理和临床特征研究。
Front Immunol. 2023 Jan 5;13:1113070. doi: 10.3389/fimmu.2022.1113070. eCollection 2022.
9
Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon.聚乙二醇干扰素治疗 HBsAg<200IU/ml 的非活动 HBsAg 携带者的临床治愈率。
Front Immunol. 2022 Dec 23;13:1091786. doi: 10.3389/fimmu.2022.1091786. eCollection 2022.
10
Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.聚乙二醇干扰素 α-2a 治疗期间 HBeAg 阳性慢性乙型肝炎患者中自然杀伤细胞的功能分子表达与 HBsAg 清除相关。
Front Immunol. 2022 Nov 21;13:1067362. doi: 10.3389/fimmu.2022.1067362. eCollection 2022.

本文引用的文献

1
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up.高流行地区无症状携带者的HBsAg血清学清除:长期随访期间的显著高发生率
Hepatology. 2007 May;45(5):1187-92. doi: 10.1002/hep.21612.
2
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.基于循环乙肝病毒载量水平预测肝硬化风险。
Gastroenterology. 2006 Mar;130(3):678-86. doi: 10.1053/j.gastro.2005.11.016.
3
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.血清乙型肝炎病毒DNA水平生物梯度上肝细胞癌的风险。
JAMA. 2006 Jan 4;295(1):65-73. doi: 10.1001/jama.295.1.65.
4
Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline.与B基因型相比,C基因型乙型肝炎病毒感染与乙型肝炎再激活及进展为肝硬化的风险更高相关:一项对基线时转氨酶水平正常的乙肝e抗原阳性患者的纵向研究。
J Hepatol. 2005 Sep;43(3):411-7. doi: 10.1016/j.jhep.2005.03.018.
5
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.亚洲慢性乙型肝炎的预后决定因素:治疗意义。
Gut. 2005 Nov;54(11):1610-4. doi: 10.1136/gut.2005.065136. Epub 2005 May 4.
6
Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.血清转氨酶水平正常的乙肝e抗原向抗体血清学转换的自然史
Am J Med. 2004 Jun 15;116(12):829-34. doi: 10.1016/j.amjmed.2003.12.040.
7
Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.台湾乙肝携带者的乙肝病毒基因型与自发性乙肝e抗原血清学转换
J Med Virol. 2004 Mar;72(3):363-9. doi: 10.1002/jmv.10534.
8
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.与乙型肝炎病毒C基因型相比,乙型肝炎病毒B基因型与更早的HBeAg血清学转换相关。
Gastroenterology. 2002 Jun;122(7):1756-62. doi: 10.1053/gast.2002.33588.
9
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.慢性乙型肝炎患者HBeAg自然血清学转换后的长期预后。
Hepatology. 2002 Jun;35(6):1522-7. doi: 10.1053/jhep.2002.33638.
10
Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.成人慢性乙型肝炎病毒感染的自然史,重点关注肝硬化和肝细胞癌的发生情况。
J Gastroenterol Hepatol. 2000 May;15 Suppl:E25-30. doi: 10.1046/j.1440-1746.2000.02097.x.

HBsAg 携带者静止期肝炎的自发复发。

Spontaneous relapse of hepatitis in inactive HBsAg carriers.

机构信息

Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University, 199, Tung Hwa North Road, Taipei, 10591, Taiwan,

出版信息

Hepatol Int. 2007 Jun;1(2):311-5. doi: 10.1007/s12072-007-9002-9.

DOI:10.1007/s12072-007-9002-9
PMID:19669355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2716824/
Abstract

BACKGROUND/AIMS: The issue of spontaneous relapse of hepatitis in anti-HBe positive asymptomatic HBsAg carriers was rarely reported before and deserves further exploration.

METHODS

A total of 1241 anti-HBe positive asymptomatic adult HBsAg carriers were prospectively followed up. Of these, 661 (53%) were males, and the mean (+/-SD) age was 35.6 +/- 9.1 years. Relapse of hepatitis was defined as elevation of ALT more than twice the upper limit of normal accompanied by detectable serum HBV DNA by hybridization assays.

RESULTS

During a mean follow up of 12.3 years, hepatitis relapsed in 211 patients with an annual rate of 1.46%. The cumulative probabilities of hepatitis relapse were 10.2%, 17.4%, 19.3%, 20.2%, and 20.2%, respectively, after 5, 10, 15, 20, and 25 years of follow up. Multivariate analyses showed that the probability of hepatitis relapse correlated significantly with male sex (P < 0.0001) and age at entry (P = 0.007). The cumulative probability of hepatitis relapse after 20 years was 26.9% for males and only 12.5% for females, and was 13.1% for those of age <30 years at entry but increased to 29.4% for those of age 40-49 years at entry.

CONCLUSION

Hepatitis relapsed in about 20% of asymptomatic HBsAg carries during 25 years of follow up. Relapse of hepatitis occurred more frequently during earlier years of follow up. Males were more likely to have relapse of hepatitis than females. In addition, relapse of hepatitis was significantly less frequent in patients who were younger than 30 years at study entry, possibly implicating more favorable outcome of earlier HBeAg seroconversion.

摘要

背景/目的:抗 HBe 阳性无症状 HBsAg 携带者的自发性肝炎复发问题以前很少报道,值得进一步探讨。

方法

对 1241 例抗 HBe 阳性无症状成年 HBsAg 携带者进行前瞻性随访。其中男性 661 例(53%),平均(+/-SD)年龄为 35.6 +/- 9.1 岁。肝炎复发定义为 ALT 升高超过正常上限的两倍,并通过杂交检测可检测到血清 HBV DNA。

结果

在平均 12.3 年的随访中,211 例患者发生肝炎复发,年发生率为 1.46%。随访 5、10、15、20 和 25 年后,肝炎复发的累积概率分别为 10.2%、17.4%、19.3%、20.2%和 20.2%。多变量分析表明,肝炎复发的概率与性别(P < 0.0001)和入组时年龄(P = 0.007)显著相关。20 年后男性肝炎复发的累积概率为 26.9%,而女性仅为 12.5%,入组时年龄<30 岁的患者为 13.1%,但入组时年龄为 40-49 岁的患者增至 29.4%。

结论

在 25 年的随访中,约有 20%的无症状 HBsAg 携带者发生肝炎复发。肝炎复发在随访早期更为常见。男性比女性更容易发生肝炎复发。此外,在研究开始时年龄小于 30 岁的患者中,肝炎复发的频率明显较低,这可能表明 HBeAg 血清学转换较早的结果更为有利。